FFO
IONS icon

Fortitude Family Office’s Ionis Pharmaceuticals IONS Stock Holding History

Fortitude Family Office’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28K Hold
17
– – ﹤0.01% 1440
2025
Q4 		$1.34K Hold
17
– – ﹤0.01% 1336
2025
Q3 		$1.11K Hold
17
– – ﹤0.01% 1508
2025
Q2 		$672 Buy
+17
New +$556 ﹤0.01% 1672
2024
Q1 		– Sell
-14
Closed -$708 – 1036
2023
Q4 		$708 Buy
+14
New +$671 ﹤0.01% 963

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fortitude Family Office's IONS Position: Q1 2026 in Review

Fortitude Family Office held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 17 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Fortitude Family Office first reported a position in IONS in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.34K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Fortitude Family Office held 17 shares of Ionis Pharmaceuticals worth $1.28K as of Q1 2026.
  • Fortitude Family Office left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1440 holding.
  • Fortitude Family Office first reported a position in Ionis Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • Fortitude Family Office's Ionis Pharmaceuticals position peaked at $1.34K in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.